

## DAFTAR PUSTAKA

- Ahmad, S., Singh, S., Wasim, S., & Rai, S. (2021). Adverse Event following Immunization (AEFI) and COVID-19 Vaccination : A Review. *International Journal of Current Microbiology and Applied Sciences*, 10(06), 555–565. [https://www.who.int/docs/default-source/covid-19-vaccines-safety-surveillance-manual/covid19vaccines\\_manual\\_aefi\\_20210104](https://www.who.int/docs/default-source/covid-19-vaccines-safety-surveillance-manual/covid19vaccines_manual_aefi_20210104)
- Alamer, E., Alhazmi, A., Qasir, N. A., Alamer, R., Areeshi, H., Gohal, G., Qadri, M., Hashem, A. M., & Algaissi, A. (2021). Side effects of covid-19 pfizer-biontech mrna vaccine in children aged 12–18 years in saudi arabia. *Vaccines*, 9(11). <https://doi.org/10.3390/vaccines9111297>
- Alghamdi, A., Ibrahim, A., Almutairi, R., Joseph, M., Alghamdi, G., & Alhamza, A. (2021). A cross-sectional survey of side effects after COVID-19 vaccination in Saudi Arabia: male versus female outcomes. *Journal of Advanced Pharmacy Education and Research*, 11(2), 51–56. <https://doi.org/10.51847/BCWCA2QGFP>
- Ali, K., Berman, G., Zhou, H., Deng, W., Faughnan, V., Coronado-Voges, M., Ding, B., Dooley, J., Girard, B., Hillebrand, W., Pajon, R., Miller, J. M., Leav, B., & McPhee, R. (2021a). Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. *New England Journal of Medicine*, 385(24), 2241–2251. <https://doi.org/10.1056/nejmoa2109522>
- Ali, K., Berman, G., Zhou, H., Deng, W., Faughnan, V., Coronado-Voges, M., Ding, B., Dooley, J., Girard, B., Hillebrand, W., Pajon, R., Miller, J. M., Leav, B., & McPhee, R. (2021b). Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. *New England Journal of Medicine*, 385(24), 2241–2251. <https://doi.org/10.1056/nejmoa2109522>
- Altooq, N., Humood, A., Alajaimi, A., Alenezi, A. F., Janahi, M., AlHaj, O., & Jahrami, H. (2022). The role of micronutrients in the management of COVID-19 and optimizing vaccine efficacy. In *Human Nutrition and Metabolism* (Vol. 27). Elsevier B.V. <https://doi.org/10.1016/j.hnm.2022.200141>
- Barlina, R. (2004). Potensi Buah Kelapa Muda Untuk Kesehatan dan Pengolahannya. *Perspektif*, 3(2).
- Bellavite, P. (2020). Causality assessment of adverse events following immunization: The problem of multifactorial pathology. *F1000Research*, 9. <https://doi.org/10.12688/f1000research.22600.1>

- Boretti, A., & Banik, B. K. (2021). Zinc role in Covid-19 disease and prevention. *Vacunas*. <https://doi.org/10.1016/j.vacun.2021.08.003>
- Bralianti, P. D., & Akbar, F. N. (2021). Covid-19 Vaccines and its Adverse Events Following Immunization( AEFI) In Indonesia| bralianti | The Avicenna Medical Journal. *The Avicenna Medical Journal*, 2(1), 19–27.
- Brenza, A. (2021). *I Didn't get side effects from my COVID-19 vaccine Am I Still protected ?*
- Broderick, R., Fuchs, K. H., Breithaupt, W., Varga, G., Schulz, T., Babic, B., Lee, A., Musial, F., & Horgan, S. (2020). Clinical Presentation of Gastroesophageal Reflux Disease: A Prospective Study on Symptom Diversity and Modification of Questionnaire Application. *Digestive Diseases*, 38(3), 188–195. <https://doi.org/10.1159/000502796>
- Cai, J., Deng, Y., Li, G., Tang, M., & Liang, H. (2021). Comment on “COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities.” *European Journal of Pediatrics*, 180(10), 3251–3252. <https://doi.org/10.1007/s00431-021-04036-9>
- Camacho Moll, M. E., Salinas Martínez, A. M., Tovar Cisneros, B., García Onofre, J. I., Navarrete Floriano, G., & Bermúdez de León, M. (2022). Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population. *Frontiers in Public Health*, 10. <https://doi.org/10.3389/fpubh.2022.834744>
- CDC. (2021a). Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine — United States, December 14–23, 2020. In *Morbidity and Mortality Weekly Report* (Issues 46–51). <https://doi.org/10.1111/ajt.16516>
- CDC. (2021b). *Vaccines & Immunizations*. [Www.Cdc.Gov. https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm](https://www.cdc.gov/vaccines/vac-gen/imz-basics.htm)
- CDC. (2022). *Safety of COVID-19 Vaccines*. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html>
- Chan, E. W. W., Leung, M. T. Y., Lau, L. K. W., Leung, J., Lum, D., Wong, R. S. M., Li, X., Chui, C. S. L., Wan, E. Y. F., Wong, C. K. H., Chan, E. W. Y., Ip, P., Wong, I. C. K., & Lai, F. T. T. (2022). Comparing self-reported

- reactogenicity between adolescents and adults following the use of BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine: a prospective cohort study. *International Journal of Infectious Diseases*, 116, 47–50. <https://doi.org/10.1016/j.ijid.2021.12.354>
- Channappanavar, R., Zhao, J., & Perlman, S. (2014). T cell-mediated immune response to respiratory coronaviruses. *Immunologic Research*, 59(1–3), 118–128. <https://doi.org/10.1007/s12026-014-8534-z>
- Chen, F., He, Y., & Shi, Y. (2022). Parents’ and Guardians’ Willingness to Vaccinate Their Children against COVID-19: A Systematic Review and Meta-Analysis. In *Vaccines* (Vol. 10, Issue 2). MDPI. <https://doi.org/10.3390/vaccines10020179>
- CMC. (2021). *What to know about side effects COVID-19 vaccine* .
- Council for International Organizations of Medical Sciences (CIOMS). (2012). Definition and Application of Terms for Vaccine Pharmacovigilance. In *Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance*. [www.who.int/bookorders](http://www.who.int/bookorders)
- Creech, C. B., Walker, S. C., & Samuels, R. J. (2021). SARS-CoV-2 Vaccines. *JAMA Insight*, 325(13), 1318–1320.
- Cucinotta, D., & Vanelli, M. (2020). WHO declares COVID-19 a pandemic. *Acta Biomedica*, 91(1), 157–160. <https://doi.org/10.23750/abm.v91i1.9397>
- Dalton, B., Bartholdy, S., Robinson, L., Solmi, M., Ibrahim, M. A. A., Breen, G., Schmidt, U., & Himmerich, H. (2018). A meta-analysis of cytokine concentrations in eating disorders. In *Journal of Psychiatric Research* (Vol. 103, pp. 252–264). Elsevier Ltd. <https://doi.org/10.1016/j.jpsychires.2018.06.002>
- Dancer, S. J., Tang, J. W., Marr, L. C., Miller, S., Morawska, L., & Jimenez, J. L. (2020). Putting a balance on the aerosolization debate around SARS-CoV-2. *Journal of Hospital Infection*, 105(3), 569–570. <https://doi.org/10.1016/j.jhin.2020.05.014>
- Dinleyici, E. Ç. (2021). COVID-19 Vaccines in Children and Adolescents. *Cam and Sakura Medical Journal*, 1(3), 80–89. <https://doi.org/10.4274/csmedj.galenos.2021.2021-12-4>
- Dirjen P2P Kemenkes RI. (2021). *Apa manfaat vaksinasi COVID-19*. [Http://P2ptm.Kemkes.Go.Id/](http://P2ptm.Kemkes.Go.Id/). <http://p2ptm.kemkes.go.id/infographic->

p2ptm/hipertensi-penyakit-jantung-dan-pembuluh-darah/apa-manfaat-vaksinasi-covid-19

- Dungga, E. F., & Dulanim, A. (2021). Hubungan Intensitas Penggunaan Smartphone dengan Kualitas dan Kuantitas tidur pada Remaja. *Jambura Nursing Journal* , 3(2).
- Esakandari, H., Nabi-afjadi, M., Fakkari-afjadi, J., Farahmandian, N., Miresmaeili, S., & Bahreini, E. (2020). A comprehensive review of COVID-19 characteristics. *Biological Procedures Online*, 2, 1–10.
- Etminan, M., Sodhi, M., & Ganjizadeh-Zavareh, S. (2021). Should Antipyretics Be Used to Relieve Acute Adverse Events Related to COVID-19 Vaccines? In *Chest* (Vol. 159, Issue 6, pp. 2171–2172). Elsevier Inc. <https://doi.org/10.1016/j.chest.2021.01.080>
- Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., Dold, C., Faust, S. N., Finn, A., Flaxman, A. L., Hallis, B., Heath, P., Jenkin, D., Lazarus, R., Makinson, R., ... Yau, Y. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet*, 396(10249), 467–478. [https://doi.org/10.1016/S0140-6736\(20\)31604-4](https://doi.org/10.1016/S0140-6736(20)31604-4)
- Freeman, D., Lambe, S., Yu, L. M., Freeman, J., Chadwick, A., Vaccari, C., Waite, F., Rosebrock, L., Petit, A., Vanderslott, S., Lewandowsky, S., Larkin, M., Innocenti, S., McShane, H., Pollard, A. J., & Loe, B. S. (2021). Injection fears and COVID-19 vaccine hesitancy. *Psychological Medicine*. <https://doi.org/10.1017/S0033291721002609>
- Frenck, R. W., Klein, N. P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J. L., Walter, E. B., Senders, S., Bailey, R., Swanson, K. A., Ma, H., Xu, X., Koury, K., Kalina, W. v., Cooper, D., Jennings, T., Brandon, D. M., Thomas, S. J., ... Gruber, W. C. (2021). Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. *New England Journal of Medicine*, 385(3), 239–250. <https://doi.org/10.1056/nejmoa2107456>
- Giuriato, G., Pedrinolla, A., Federico, S., & Venturelli, M. (2018). Muscle cramps: A comparison of the two-leading hypothesis. In *Journal of Electromyography and Kinesiology* (Vol. 41, pp. 89–95). Elsevier Ltd. <https://doi.org/10.1016/j.jelekin.2018.05.006>

- Guzmán-Martínez, O., Guardado, K., de Guevara, E. L., Navarro, S., Hernández, C., Zenteno-Cuevas, R., & Montero, H. (2021). Igg antibodies generation and side effects caused by ad5-ncov vaccine (Cansino biologics) and bnt162b2 vaccine (pfizer/biontech) among mexican population. *Vaccines*, 9(9), 1–9. <https://doi.org/10.3390/vaccines9090999>
- Hafidz, A., Ahmad, S., Siddqui, S. A., Ahmad, M., & Shruti. (2020). A Review of COVID-19 (Coronavirus Disease-2019) Diagnosis, Treatments and Prevention. *Eurasian Journal of Medicine and Oncology*, 4(2), 116–125. <https://doi.org/10.14744/ejmo.2020.90853>
- Han, B., Song, Y., Li, C., Yang, W., Ma, Q., Jiang, Z., Li, M., Lian, X., Jiao, W., Wang, L., Shu, Q., Wu, Z., Zhao, Y., Li, Q., & Gao, Q. (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. *The Lancet Infectious Diseases*, 21(12), 1645–1653. [https://doi.org/10.1016/S1473-3099\(21\)00319-4](https://doi.org/10.1016/S1473-3099(21)00319-4)
- Hanifah, S. (2021). *Cek Fakta: Minum Susu Steril Tak Terbukti Bisa Netralkan Vaksin COVID-19*.
- Haumeni, J. W., & Elon, Y. (2022). Tingkat Kecemasan Remaja dalam Penerimaan Vaksin COVID-19. *Community of Publishing in Nursing (COPING)*, 10(2), 130–135.
- Hause, A. M., Gee, J., Baggs, J., & Abara, W. E. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 years-United States, December 14, 2020-July 16, 2021. In *Morbidity and Mortality Weekly Report* (Vol. 70, Issue 2). <https://doi.org/10.1001/jama.2021.0600>
- Hervé, C., Laupèze, B., del Giudice, G., Didierlaurent, A. M., & da Silva, F. T. (2019). The how's and what's of vaccine reactogenicity. In *npj Vaccines* (Vol. 4, Issue 1). Nature Publishing Group. <https://doi.org/10.1038/s41541-019-0132-6>
- Hoffman, Y., Palgi, Y., Goodwin, R., Ben-Ezra, M., & Greenblatt-Kimron, L. (2021). A storm in a teacup: Older adults' low prevalence of COVID-19 vaccine side-effects and their link with vaccination anxiety. In *International Psychogeriatrics* (Vol. 33, Issue 12, pp. 1335–1337). Cambridge University Press. <https://doi.org/10.1017/S1041610221001071>
- Hoffmann, M. A., Wieler, H. J., Enders, P., Buchholz, H. G., & Plachter, B. (2021). Age- and sex-graded data evaluation of vaccination reactions after initial

- injection of the bnt162b2 mrna vaccine in a local vaccination center in germany. *Vaccines*, 9(8). <https://doi.org/10.3390/vaccines9080911>
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., ... Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, 395(10223), 497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
- IDAI. (2021a). *Rekomendasi Ikatan Dokter Anak Indonesia pemberian vaksin COVID\_19 (Coronavac) pada anak usia 6 tahun ke atas.*
- IDAI. (2021b). *Rekomendasi Ikatan Dokter Anak Indonesia terkait Pemberian Vaksin COVID-19 pada Anak dan Remaja.*
- Izzatinnisa, & Utami, U. dan A. M. (2020). Jurnal Riset Biologi dan Aplikasinya. *Jurnal Riset Biologi Dan Aplikasinya*, 2(50), 18–25.
- Jackson, L. A., Anderson, E. J., Roupael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., McDermott, A., Flach, B., Doria-Rose, N. A., Corbett, K. S., Morabito, K. M., O'Dell, S., Schmidt, S. D., Swanson, P. A., ... Beigel, J. H. (2020). An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. *New England Journal of Medicine*, 383(20), 1920–1931. <https://doi.org/10.1056/nejmoa2022483>
- Kadali, R. A. K., Janagama, R., Peruru, S., Gajula, V., Madathala, R. R., Chennaiahgari, N., & Malayala, S. v. (2021). Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. *Journal of Medical Virology*, 93(7), 4420–4429. <https://doi.org/10.1002/jmv.26996>
- Kamel, A. M., Monem, M. S. A., Sharaf, N. A., Magdy, N., & Farid, S. F. (2021). Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials. *Reviews in Medical Virology*, 1–21. <https://doi.org/10.1002/rmv.2258>
- Kang, Y. M., Lim, J., Choe, K. W., Lee, K. D., Jo, D. H., Kim, M. J., Kim, J. M., & Kim, K. N. (2021). Reactogenicity after the first and second doses of bnt162b2 mrna coronavirus disease vaccine: A single-center study. *Clinical and Experimental Vaccine Research*, 10(3), 282–289. <https://doi.org/10.7774/cevr.2021.10.3.282>

- Karshikoff, B., Sundelin, T., & Lasselin, J. (2017). Role of inflammation in human fatigue: Relevance of multidimensional assessments and potential neuronal mechanisms. In *Frontiers in Immunology* (Vol. 8, Issue JAN). Frontiers Media S.A. <https://doi.org/10.3389/fimmu.2017.00021>
- Kemkes RI. (2021a). *Dashboard COVID-19*. <https://covid19.kemkes.go.id/dashboard/covid-19>
- Kemkes RI. (2021b). *Vaksinasi COVID-19 Nasional*. <https://vaksin.kemkes.go.id/#/vaccines>
- Kementrian Komunikasi dan Informatika RI. (2021). *Kominfo Temukan 2.164 Sebaran Hoaks Vaksin Covid-19 di Facebook*. <https://aptika.kominfo.go.id/2021/11/kominfo-temukan-2-164-sebaran-hoaks-vaksin-covid-19-di-facebook/>
- Kim, J. H., Kim, J. H., & Woo, C. G. (2022). Clinicopathological Characteristics of Inflammatory Myositis Induced by COVID-19 Vaccine (Pfizer-BioNTech BNT162b2): A Case Report. *Journal of Korean Medical Science*, 37(11). <https://doi.org/10.3346/jkms.2022.37.e91>
- Kominfo RI. (2021a). *3 Pilar Utama Penanganan COVID-19 di Indonesia*. [Www.Covid19.Go.Id. https://covid19.go.id/pertolongan-pertama/3-pilar-utama-penanganan-covid-19-di-indonesia](https://www.covid19.go.id/pertolongan-pertama/3-pilar-utama-penanganan-covid-19-di-indonesia)
- Kominfo RI. (2021b). *(HOAKS) Air Kelapa Hijau Sebagai Penawar Vaksin*. [Https://M.Kominfo.Go.Id/](https://M.Kominfo.Go.Id/)
- Kritz F. (2021). *Coronavirus FAQ : Why do so many folks say to drink lots of water before your vaccine ?* .
- Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020). The incubation period of coronavirus disease 2019 (CoVID-19) from publicly reported confirmed cases: Estimation and application. *Annals of Internal Medicine*, 172(9), 577–582. <https://doi.org/10.7326/M20-0504>
- Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., Zhang, Q., & Wu, J. (2020). Coronavirus infections and immune responses. *Journal of Medical Virology*, 92(4), 424–432. <https://doi.org/10.1002/jmv.25685>
- Li, H., Liu, S., Yu, X., Tang, S., & Tang, C. (2020). *Coronavirus disease 2019 (COVID-19): January*.

- Li, X., Geng, M., Peng, Y., Meng, L., & Lu, S. (2020). Molecular immune pathogenesis and diagnosis of COVID-19. *Journal of Pharmaceutical Analysis*, *10*(2), 102–108. <https://doi.org/10.1016/j.jpha.2020.03.001>
- Li, Y., Tenchov, R., Smoot, J., Liu, C., Watkins, S., & Zhou, Q. (2021). A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. *ACS Central Science*, *7*(4), 512–533. <https://doi.org/10.1021/acscentsci.1c00120>
- Liao, J., Fan, S., Chen, J., Wu, J., Xu, S., Guo, Y., Li, C., Zhang, X., Wu, C., Mou, H., Song, C., Li, F., Wu, G., Zhang, J., Guo, L., Liu, H., Lv, J., Xu, L., & Lang, C. (2020). Epidemiological and Clinical Characteristics of COVID-19 in Adolescents and Young Adults. *Innovation(China)*, *1*(1), 100001. <https://doi.org/10.1016/j.xinn.2020.04.001>
- Logunov, D. Y., Dolzhikova, I. v., Shcheblyakov, D. v., Tukhvatulin, A. I., Zubkova, O. v., Dzharullaeva, A. S., Kovyrshina, A. v., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., Botikov, A. G., Izhaeva, F. M., Popova, O., Ozharovskaya, T. A., Esmagambetov, I. B., Favorskaya, I. A., Zrelkin, D. I., Voronina, D. v., Shcherbinin, D. N., ... Gintsburg, A. L. (2021). Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *The Lancet*, *397*(10275), 671–681. [https://doi.org/10.1016/S0140-6736\(21\)00234-8](https://doi.org/10.1016/S0140-6736(21)00234-8)
- Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020). COVID-19: Transmission, prevention, and potential therapeutic opportunities. *Clinica Chimica Acta*, *508*(May), 254–266. <https://doi.org/10.1016/j.cca.2020.05.044>
- Lotfi, M., Hamblin, M, R., & Rezaei, N. (2020). COVID-19: transmission, prevention, and potential therapeutic opportunities. *Clinica Chimica Acta*, *508*(January), 254–266. [www.elsevier.com/locate/cca](http://www.elsevier.com/locate/cca) Review
- Lv, M., Luo, X., Shen, Q., Lei, R., Liu, X., Liu, E., Li, Q., & Chen, Y. (2021). Safety, immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: A systematic review. *Vaccines*, *9*(10), 1–13. <https://doi.org/10.3390/vaccines9101102>
- Mantovani, A. (2020). Coronavirus disease 2019 ( COVID-19 ) in children and / or adolescents : a meta-analysis. *Pediatric Research*, *2019*(June).
- Masuka, J. T., & Khoza, S. (2019). Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI):



- An analysis of spontaneous reports in Vigibase® from 1997 to 2017. *BMC Public Health*, 19(1), 1–11. <https://doi.org/10.1186/s12889-019-7482-x>
- Mellet, J., & Pepper, M. S. (2021). A covid-19 vaccine: Big strides come with big challenges. *Vaccines*, 9(1), 1–14. <https://doi.org/10.3390/vaccines9010039>
- Notoatmodjo, S. (2012). *Metodologi Penelitian Kesehatan*. PT Rineka Cipta.
- Nugroho, W. D., C, W. I., Alanish, S. T., Istiqomah, N., & Cahyasari, I. (2020). Literature Review : Transmisi Covid-19 dari Manusia ke Manusia Di Asia. *Jurnal of Bionursing*, 2(2), 101–112. <http://bionursing.fikes.unsoed.ac.id/bion/index.php/bionursing/article/view/51>
- Oh, H. K., Kim, E. K., Hwang, I., Kim, T. E., Lee, Y. K., Lee, E., & Lee, Y. K. (2021). COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021. *Osong Public Health and Research Perspectives*, 12(4), 264–268. <https://doi.org/10.24171/J.PHRP.2021.0157>
- Ooi, E. E., Dhar, A., Petruschke, R., Loch, C., Buchy, P., & Low, J. G. H. (2022). Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. In *npj Vaccines* (Vol. 7, Issue 1). Nature Research. <https://doi.org/10.1038/s41541-022-00453-5>
- Ophinni, Y., Hasibuan, A. S., Widhani, A., Maria, S., Koesnoe, S., Yunihastuti, E., Karjadi, T. H., Rengganis, I., & Djauzi, S. (2020). COVID-19 Vaccines: Current Status and Implication for Use in Indonesia. *Acta Medica Indonesiana*, 52(4), 388–412.
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. v., Cooper, D., Frenck, R. W., Hammitt, L. L., ... Gruber, W. C. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New England Journal of Medicine*, 383(27), 2603–2615. <https://doi.org/10.1056/nejmoa2034577>
- Polish Jay. (2021). *Why you might get muscle cramps after The COVID-19 vaccine*.
- Pormohammad, A., Zarei, M., Ghorbani, S., Mohammadi, M., Razizadeh, M. H., Turner, D. L., & Turner, R. J. (2021). Efficacy and safety of covid-19 vaccines: A systematic review and meta-analysis of randomized clinical trials. In *Vaccines* (Vol. 9, Issue 5). MDPI AG. <https://doi.org/10.3390/vaccines9050467>

- Redaktion. (2017). *Phases of sleep are important for physical regeneration* .  
Www.Simplyhealthysleep.Com.
- Rizal, J. G. (2021). *Benarkah Minum Air Kelapa dapat menetralkan efek samping vaksin ?* . Kompas.Com.
- Sahebnasagh, A., Avan, R., Saghafi, F., Mojtahedzadeh, M., Sadremomtaz, A., Arasteh, O., Tanzifi, A., Faramarzi, F., Negarandeh, R., Safdari, M., Khataminia, M., Rezai Ghaleno, H., Habtemariam, S., & Khoshi, A. (2020). Pharmacological treatments of COVID-19. In *Pharmacological Reports* (Vol. 72, Issue 6). <https://doi.org/10.1007/s43440-020-00152-9>
- Satgas COVID-19. (2021). *Lakukan Semua: 3M, 3T, dan Vaksinasi*.  
<https://covid19.go.id/artikel/2020/12/08/lakukan-semua-3m-3t-dan-vaksinasi>
- Schauer, J., Buddhe, S., Colyer, J., Sagiv, E., Law, Y., Mallenahalli Chikkabyrappa, S., & Portman, M. A. (2021). Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents. *Journal of Pediatrics*, 238, 317–320.  
<https://doi.org/10.1016/j.jpeds.2021.06.083>
- Schmitz, N. C. M., van der Werf, Y. D., & Lammers-van der Holst, H. M. (2022a). The Importance of Sleep and Circadian Rhythms for Vaccination Success and Susceptibility to Viral Infections. *Clocks & Sleep*, 4(1), 66–79.  
<https://doi.org/10.3390/clockssleep4010008>
- Schmitz, N. C. M., van der Werf, Y. D., & Lammers-van der Holst, H. M. (2022b). The Importance of Sleep and Circadian Rhythms for Vaccination Success and Susceptibility to Viral Infections. *Clocks & Sleep*, 4(1), 66–79.  
<https://doi.org/10.3390/clockssleep4010008>
- Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. *Journal of Advanced Research*, 24, 91–98.  
<https://doi.org/10.1016/j.jare.2020.03.005>
- Shivani Singh, S. A., & Silky Rai, S. W. (2021). Adverse Event following Immunization (AEFI) and COVID-19 Vaccination: A Review. *International Journal of Current Microbiology and Applied Sciences*, 10(6), 555–565.  
<https://doi.org/10.20546/ijcmas.2021.1006.061>
- Soto, J. A., Melo-González, F., Gutierrez-Vera, C., Schultz, B. M., Berríos-Rojas, R. v, Rivera-Pérez, D., Piña-Iturbe, A., Hoppe-Elsholz, G., Duarte, L. F., Vázquez, Y., Moreno-Tapia, D., Ríos, M., Palacios, P. A., Garcia-Betancourt,

- R., Santibañez, Á., Mendez, C., Diethelm-Varela, B., Astudillo, P., Calvo, M., ... Bueno, S. M. (2022). An inactivated SARS-CoV-2 vaccine is safe and induces humoral and cellular immunity against virus variants in healthy children and adolescents in Chile. *MedRxiv Preprint*. <https://doi.org/10.1101/2022.02.15.22270973>
- Speiser, D. E., & Bachmann, M. F. (2020). Covid-19: Mechanisms of vaccination and immunity. *Vaccines*, 8(3), 1–22. <https://doi.org/10.3390/vaccines8030404>
- Suryoadji, K. A., & Nugraha, D. A. (2020). *Aktivitas Fisik pada Anak dan Remaja Selama Pandemi COVID-19: A Systematic Review*.
- Sutardi, A. Q. I., & Ramatillah, D. L. (2022). Evaluation Comparison Between Sinovac and Pfizer Vaccine Among Indonesian Children and Teenager Under 18 Years Old. *International Journal of Applied Pharmaceutics*, 14(Special issue 2), 22–30. <https://doi.org/10.22159/ijap.2022.v14s2.44745>
- Taylor, S., & Asmundson, G. J. G. (2021). Immunization stress-related responses: Implications for vaccination hesitancy and vaccination processes during the COVID-19 pandemic. In *Journal of Anxiety Disorders* (Vol. 84). Elsevier Ltd. <https://doi.org/10.1016/j.janxdis.2021.102489>
- UNICEF. (2021). Vaksin COVID-19 & KIPI. *Unicef*. [https://www.unicef.org/indonesia/id/media/9896/file/Booklet\\_Vaksin\\_COVID-19\\_&\\_KIPI.pdf](https://www.unicef.org/indonesia/id/media/9896/file/Booklet_Vaksin_COVID-19_&_KIPI.pdf)
- Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., Oliveira, T. Y., Yang, Z., Abernathy, M. E., Huey-Tubman, K. E., Hurley, A., Turroja, M., West, K. A., Gordon, K., Millard, K. G., ... Nussenzweig, M. C. (2021). mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature*, 592(7855), 616–622. <https://doi.org/10.1038/s41586-021-03324-6>
- WHO. (2020). Novel Coronavirus (2019-nCov) Situation Report. In *WHO* (Vol. 1, Issue JANUARY). <https://doi.org/10.13070/mm.en.10.2867>
- WHO. (2021). *COVID-19 vaccines*. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines>
- WHO. (2022). *WHO Coronavirus (COVID-19) Dashboard*. [Www.Covid19.Who.Int](https://covid19.who.int/). <https://covid19.who.int/>

- Wirunpan, M. (2021). Knowledge, attitudes, and willingness of adolescents towards coronavirus disease 2019 vaccine in Bangkok, Thailand. *International Journal of Medical Science and Public Health*, 10(2), 1. <https://doi.org/10.5455/ijmsph.2021.07075202111082021>
- World Health Organization. (2019). *IMMUNIZATION STRESS-RELATED RESPONSES*.
- World Health Organization. (2020). *Listings of WHO's response to COVID-19*. WHO. <https://www.who.int/news/item/29-06-2020-covidtimeline>
- World Health Organization. (2022, April 13). *COVID-19 advice for the public: Getting Vaccinated*. Wwww.Who.Int.
- World Health Organization (WHO). (2013). Vaccine Safety Basics learning manual. In *World Health Organization (WHO)*. WHO Press. [http://www.who.int/vaccine\\_safety/initiative/tech\\_support/Vaccine-safety-E-course-manual.pdf?ua=1](http://www.who.int/vaccine_safety/initiative/tech_support/Vaccine-safety-E-course-manual.pdf?ua=1)
- World Health Organization (WHO). (2019). *IMMUNIZATION STRESS-RELATED RESPONSES*.
- Yan, Z., Yang, M., & Lai, C. L. (2021). Covid-19 vaccines: A review of the safety and efficacy of current clinical trials. *Pharmaceuticals*, 14(5). <https://doi.org/10.3390/ph14050406>
- Yuki, K., Fujiogi, M., & Koutsogiannaki, S. (2020). COVID-19 pathophysiology: A review. *Clinical Immunology*, 215(April). <https://doi.org/10.1016/j.clim.2020.108427>
- Zavala-Solares, M. R., Fonseca-Camarillo, G., Valdovinos, M., Granados, J., Grajales-Figueroa, G., Zamora-Nava, L., Aguilar-Olivos, N., Valdovinos-García, L. R., & Yamamoto-Furusho, J. K. (2021). Gene expression profiling of inflammatory cytokines in esophageal biopsies of different phenotypes of gastroesophageal reflux disease: a cross-sectional study. *BMC Gastroenterology*, 21(1). <https://doi.org/10.1186/s12876-021-01707-7>
- Zhang, J. M., & An, J. (2007). Cytokines, inflammation, and pain. In *International Anesthesiology Clinics* (Vol. 45, Issue 2, pp. 27–37). <https://doi.org/10.1097/AIA.0b013e318034194e>
- Zheng, Y. J., Wang, X. C., Feng, L. Z., Xie, Z. de, Jiang, Y., Lu, G., Li, X. W., Jiang, R. M., Deng, J. K., Liu, M., Xu, B. P., Wei, Z., Liu, G., Lu, X. X., Jin, R. M., Liu, Z. S., Shang, Y. X., Shu, S. N., Bai, Y., ... Shen, K. L. (2021).

Expert consensus on COVID-19 vaccination in children. In *World Journal of Pediatrics* (Vol. 17, Issue 5, pp. 449–457). Institute of Pediatrics of Zhejiang University. <https://doi.org/10.1007/s12519-021-00465-6>

Zhu, F., Jin, P., Zhu, T., Wang, W., Ye, H., Pan, H., Hou, L., Li, J., Wang, X., Wu, S., Wang, Y., Gou, J., Huang, H., Wu, H., Wang, X., & Chen, W. (2021). Safety and Immunogenicity of a Recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged  $\geq 6$  Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial. *Clinical Infectious Diseases*, 2019(Xx Xxxx), 1–9. <https://doi.org/10.1093/cid/ciab845>

Zhu, J. S., Zhang, M. X., Chien, C. W., Yang, W. Y., Shi, G. F., Qiu, S., Tung, T. H., & Chen, H. X. (2021). Sex Differences in Adverse Reactions to an Inactivated SARS-CoV-2 Vaccine Among Medical Staff in China. *Frontiers in Medicine*, 8. <https://doi.org/10.3389/fmed.2021.731593>

# **LAMPIRAN-LAMPIRAN**

**Lampiran 1 :**

**LEMBAR PENJELASAN PENELITIAN**

Assalamualaikum Warahmatullahi Wabarakatuh

Saya yang bertanda tangan dibawah ini adalah mahasiswi Ilmu Keperawatan Fakultas Keperawatan Universitas Hasanuddin atas **nama A.Sri Mulyani, NIM R011181012**, saat ini saya sedang mengerjakan penelitian yang berjudul **“Gambaran Kejadian Ikutan Kejadian Pasca Imunisasi (KIPI) pada Remaja yang telah Menerima Vaksinasi COVID-19 di Kota Makassar”**.

Penelitian ini bertujuan untuk mengetahui gambaran reaksi KIPI pada remaja yang telah menerima vaksinasi COVID-19 di kota Makassar. Adapun manfaat dari penelitian ini yaitu untuk menjadi sumber informasi masyarakat guna menambah wawasan dan pengetahuan dalam meningkatkan derajat kesehatan khususnya pencapaian *herd immunity* menghadapi pandemi COVID-19.


Dalam penelitian ini akan dilakukan pengambilan data berupa data demografi, informasi vaksin, reaksi KIPI vaksin COVID-19, periode waktu reaksi KIPI serta aktivitas saat mengalami KIPI. Kuesioner diperkirakan diselesaikan dalam waktu  $\pm$  5 menit. Kerahasiaan semua informasi yang diperoleh oleh peneliti akan dijamin keamanannya dan hanya data tertentu saja yang akan disajikan atau dilaporkan pada hasil penelitian.

Untuk itu, peneliti mengharapkan kesediaan dan kerja sama saudara dalam mengikuti penelitian ini. Apabila sewaktu-waktu ada hal yang ingin dikonfirmasi terkait penelitian silahkan menghubungi peneliti melalui *whatsapp* 082348452615. Atas kesediaan saudara dan kerja samanya peneliti ucapkan terima kasih.

Wassalamualaikum Warahmatullahi Wabarakatuh

Makassar, 5 April 2022

Peneliti

  
A. Sri Mulyani

Penanggung Jawab Penelitian :

Nama : A.Sri Mulyani

Alamat : Jalan Sahabat Raya No.2 UNHAS

No.Telepon : 082348452615

**Lampiran 2 :**

**LEMBAR PERSETUJUAN RESPONDEN**

Saya yang bertanda tangan dibawah ini :

Nama :

Umur :

Alamat :

Setelah membaca dan mengerti penjelasan yang diberikan mengenai tujuan, manfaat dan apa yang akan dilakukan pada penelitian **“Gambaran Kejadian Ikutan Kejadian Pasca Imunisasi (KIPI) pada Remaja yang telah Menerima Vaksinasi COVID-19 di Kota Makassar”**, menyatakan setuju untuk ikut dalam penelitian ini secara sukarela dan tanpa paksaan dari pihak manapun, sehingga saya bisa menolak ikut atau mengundurkan diri dari penelitian ini, berhak bertanya atau meminta penjelasan kepada peneliti bila masih ada hal yang belum jelas.

Dengan demikian, saya yang bertanda tangan dibawah ini menyatakan bersedia dan tidak keberatan untuk memberikan informasi dan menjawab pertanyaan-pertanyaan yang diajukan kepada saya. Saya percaya bahwa keamanan dan kerahasiaan penelitian ini dijamin dan saya menyetujui semua data saya dari penelitian ini untuk disajikan dalam bentuk lisan maupun tulisan.

Demikian pernyataan ini saya buat dengan penuh tanggung jawab untuk dipergunakan sebagaimana mestinya.

Makassar, 2022

Peneliti

Responden



A.Sri Mulyani

(.....)



### Lampiran 3

#### KUESIONER PENELITIAN

##### A. Identitas Responden

1. Nama/Inisial Responden : .....
2. Umur : ..... 4. Nama Sekolah/Kelas : .....
3. Jenis Kelamin :..... 5. Nomor Tlp/Whatsapp : .....

##### B. Informasi Vaksin COVID-19

1. Jenis vaksin yang diterima : *(silahkan centang yang sesuai)*
  - Coronavac (Sinovac)
  - Pfizer
2. Kapan waktu penerimaan vaksin terakhir *(bisa dilihat di sertifikat vaksin)*  
Jawaban (DD/MM/YYYY) : .....

##### C. Pertanyaan Kriteria Eksklusi

1. Apakah sudah mendapatkan vaksinasi COVID-19 suntikan kedua?
  - a. Ya
  - b. Tidak

##### D. Reaksi KIPI :

**(KIPI adalah efek samping yang bisa dirasakan seseorang setelah menerima vaksinasi)**

##### 1. Reaksi KIPI pada **DOSIS PERTAMA** :

*(silahkan centang pada reaksi yang anda rasakan dalam kurun waktu 7 hari setelah vaksin)*

- |   |   |
|---|---|
| <input type="checkbox"/> Nyeri pada lokasi suntikan | <input type="checkbox"/> Kemerahan di lokasi suntikan |
| <input type="checkbox"/> Bengkak di lokasi suntikan | <input type="checkbox"/> Demam                        |
| <input type="checkbox"/> Sakit kepala               | <input type="checkbox"/> Pusing                       |
| <input type="checkbox"/> Mual/Muntah                | <input type="checkbox"/> Nyeri otot                   |
| <input type="checkbox"/> Kelelahan                  | <input type="checkbox"/> Menggigil                    |

- Mengantuk
- Perubahan nafsu makan
- Kesulitan bernafas
- Nyeri dada
- Tidak ada

2. Jika terdapat reaksi KIPI, berapa lama reaksi dirasakan ?

*(jika dipertanyaan sebelumnya memilih “tidak ada” maka silahkan pilih “tidak mengalami KIPI”*

- a. Tidak mengalami KIPI
- b. < 24 jam
- c. 24-72 jam
- d. >72 jam

3. Tindakan yang dilakukan saat mengalami KIPI vaksin COVID-19 dosis 1

Contoh : Minum obat penurun panas, istirahat yang cukup, ke pelayanan kesehatan, dll

Jawaban : .....

4. Dapat menjalani aktivitas sehari hari secara normal saat mengalami KIPI vaksin COVID-19 dosis 1

- a. Tidak mengalami KIPI
- b. Ya
- c. Tidak

5. Vaksinasi **DOSIS KEDUA** :

a. Reaksi KIPI :

*(silahkan centang pada reaksi yang anda rasakan dalam kurun waktu 7 hari setelah vaksin)*

- Nyeri pada lokasi suntikan
- Kemerahan di lokasi suntikan
- Bengkak di lokasi suntikan
- Demam
- Sakit kepala
- Pusing
- Mual/Muntah
- Nyeri otot

- Kelelahan
- Menggigil
- Mengantuk
- Perubahan nafsu makan
- Kesulitan bernafas
- Nyeri dada
- Tidak ada

6. Jika terdapat reaksi KIPI, berapa lama reaksi dirasakan

- a. Tidak mengalami KIPI
- b. < 24 jam
- c. 24-72 jam
- d. >72 jam

7. Tindakan yang dilakukan saat mengalami KIPI vaksin COVID-19 dosis 2

Contoh : Minum obat penurun panas, istirahat yang cukup, ke pelayanan kesehatan, dll

Jawaban : .....

8. Dapat menjalani aktivitas sehari hari secara normal saat mengalami KIPI vaksin COVID-19 dosis 2

- a. Tidak mengalami KIPI
- b. Ya
- c. Tidak

9. Apakah memiliki reaksi lain selain efek samping yang telah ditanyakan diatas ?

Sebutkan : .....

-TERIMA KASIH ATAS PARTISIPASINYA-

## Lampiran 4 : Lembar Surat Izin Data Awal Penelitian



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,  
RISET DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN  
FAKULTAS KEPERAWATAN  
Jl. Perintis Kemerdekaan Km. 10 Makassar 90245  
Laman : [keperawatan@unhas.ac.id](mailto:keperawatan@unhas.ac.id)

No. : **688/UN4.18.1/DL.16/2022** 9 Februari 2022  
Lamp. : -  
Hal : **Permintaan Izin Observasi / Pengambilan  
Data Awal**

Yth.: Kepala Sekolah SMA NEGERI 18 MAKASSAR

di-  
MAKASSAR

Dengan hormat disampaikan bahwa dalam rangka penyelesaian studi/penyusunan skripsi bagi Mahasiswa Program Studi Ilmu Keperawatan Fakultas Keperawatan Universitas Hasanuddin, maka dengan ini mohon kiranya mahasiswa yang tersebut namanya dibawah ini :

Nama : **A. Sri Mulyani**  
NIM : **R011181012**  
Program Studi : **Ilmu Keperawatan**  
Rencana Judul : **Gambaran Kejadian Ikutan Pasca Imunisasi (KIPI) pada Remaja yang Telah Menerima Vaksinasi Covid-19 di Kota Makassar.**

Dapat diberikan izin untuk melakukan observasi dalam rangka pengambilan data awal, di Sekolah yang Bapak/Sdr. (i) pimpin, yang akan dilaksanakan pada bulan **Februari s/d Maret 2022**. Adapun metode yang digunakan dalam Pengumpulan data awal tersebut adalah **Observasi dan Wawancara, dengan tetap menerapkan protocol kesehatan.**

Demikian permohonan kami, atas bantuan dan kerjasama yang baik disampaikan terima kasih.

a.n. Dekan,  
Dekan Bidang Akademik, Riset  
dan Inovasi  
  
Syarif M., S.Kep, Ns, M.Kes., Ph.D.  
NIP. 19820419 2006041 002

Tembusan :

1. Dekan "sebagai laporan"
2. Ketua Program Studi Ilmu Keperawatan
3. Kabag. TU.



## Lampiran 5 : Lembar Surat Izin Penelitian



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,  
RISET DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN  
FAKULTAS KEPERAWATAN  
Jl. Perintis Kemerdekaan Km. 10 Makassar 90245  
Laman : [keperawatan@unhas.ac.id](mailto:keperawatan@unhas.ac.id)

No. : 1776/UN4.18.1/PT.01.04/2022 1 April 2022  
Lamp. : -  
Hal : **Permintaan Izin Penelitian**

Yth. Gubernur Provinsi Sulawesi Selatan  
C.q. Kepala Dinas Penanaman Modal dan PTSP  
Provinsi Sulawesi Selatan

MAKASSAR

Dengan hormat disampaikan bahwa dalam rangka penyelesaian studi Mahasiswa Program Studi Ilmu Keperawatan, Fakultas Keperawatan Universitas Hasanuddin, maka dengan ini kami mohon agar mahasiswa tersebut namanya di bawah ini :

Nama : **A. Sri Mulyani**  
NIM : R011181012  
Program Studi : Ilmu Keperawatan  
Rencana Judul : Gambaran Reaksi Kejadian Ikutan Pasca Imunisasi (KIPI) pada Remaja yang telah Menerima Vaksinasi COVID-19 di Kota Makassar.

Dapat diberikan izin melakukan penelitian di Dinas Pendidikan Provinsi Sulawesi Selatan, yang akan dilaksanakan pada bulan **April s/d Juni 2022**. Adapun Metode pengambilan sampel/data dengan : **kuesioner via online (google form)**.

Besar harapan kami, permohonan izin ini dapat dipertimbangkan untuk diterima.

Demikian permohonan kami, atas perhatiannya disampaikan terima kasih.

a.n. Dekan,  
Wakil Dekan Bidang Akademik, Riset  
dan Inovasi



**Syahrul, S.Kep, Ns, M.Kes., Ph.D.**  
NIP. 19820419 200604 1 002

Tembusan :

1. Dekan "sebagai laporan"
2. Ketua Program Studi Ilmu Keperawatan Fak. Keperawatan Unhas
3. Dinas Pendidikan Provinsi Sulawesi Selatan
4. Kepala Bagian Tata Usaha F-Kep-UH
5. Arsip



## Lampiran 6 : : Persetujuan Etik Penelitian



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
 KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN  
 RSPTN UNIVERSITAS HASANUDDIN  
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.  
 Contact Person: dr. Agussalim Bukhari.,MMed,PhD.,SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



### REKOMENDASI PERSETUJUAN ETIK

Nomor : 194/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 25 April 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22040148	No Sponsor Protokol	
Peneliti Utama	<b>A. Sri Mulyani</b>	Sponsor	
Judul Peneliti	Gambaran Reaksi Kejadian Ikutan Pasca Imunisasi (KIPI) pada Remaja yang telah Menerima Vaksinasi COVID-19 di Kota Makassar		
No Versi Protokol	2	Tanggal Versi	<b>21 April 2022</b>
No Versi PSP	2	Tanggal Versi	<b>21 April 2022</b>
Tempat Penelitian	Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku <b>25 April 2022</b> sampai <b>25 April 2023</b>	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	Nama <b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

## Lampiran 7 : Surat Izin Penelitian



PEMERINTAH PROVINSI SULAWESI SELATAN  
**DINAS PENANAMAN MODAL DAN PELAYANAN TERPADU SATU PINTU**  
BIDANG PENYELENGGARAAN PELAYANAN PERIZINAN

Nomor : 29328/S.01/PTSP/2022  
Lampiran :  
Perihal : Izin Penelitian

KepadaYth.  
Kepala Dinas Pendidikan Prov. Sulsel

di-  
Tempat

Berdasarkan surat Dekan Fak. Keperawatan UNHAS Makassar Nomor : 1776/UN4.18.1/PT.01.04/2022 tanggal 01 April 2022 perihal tersebut diatas, mahasiswa/peneliti dibawah ini:

Nama : **A. SRI MULYANI**  
Nomor Pokok : R011181012  
Program Studi : Ilmu Keperawatan  
Pekerjaan/Lembaga : Mahasiswa(S1)  
Alamat : Jl. P. Kemerdekaan Km. 10, Makassar

Bermaksud untuk melakukan penelitian di daerah/kantor saudara dalam rangka penyusunan Skripsi, dengan judul :

**" GAMBARAN REAKSI KEJADIAN IKUTAN PASCA IMUNISASI (KIPI) PADA REMAJA YANG TELAH MENERIMA VAKSINASI COVID-19 DI KOTA MAKASSAR "**

Yang akan dilaksanakan dari : Tgl. **18 April s/d 18 Juni 2022**

Sehubungan dengan hal tersebut diatas, pada prinsipnya kami *menyetujui* kegiatan dimaksud dengan ketentuan yang tertera di belakang surat izin penelitian. Dokumen ini ditandatangani secara elektronik dan Surat ini dapat dibuktikan keasliannya dengan menggunakan **barcode**,

Demikian surat izin penelitian ini diberikan agar dipergunakan sebagaimana mestinya.

Diterbitkan di Makassar  
Pada tanggal : 06 April 2022

A.n. GUBERNUR SULAWESI SELATAN  
Pit. KEPALA DINAS PENANAMAN MODAL DAN PELAYANAN TERPADU  
SATU PINTU PROVINSI SULAWESI SELATAN  
Selaku Administrator Pelayanan Perizinan Terpadu

**Dra. Hj. SUKARNIATY KONDOLELE, M.M.**

Pangkat : Pembina Utama Madya  
Nip : 19650606 199003 2 011

Tembusan Yth  
1. Dekan Fak. Keperawatan UNHAS Makassar di Makassar;  
2. *Pertinggal.*

SIMAP PTSP 06-04-2022



Jl. Bougenville No.5 Telp. (0411) 441077 Fax. (0411) 448936  
Website : <http://simap.sulselprov.go.id> Email : [ptsp@sulselprov.go.id](mailto:ptsp@sulselprov.go.id)  
Makassar 90231



**Lampiran 8 : Master Tabel Data Demografi Uji Validitas dan Reliabilitas**

No. Responden	Usia	Jenis Kelamin	Jenis Vaksin
1	3	2	1
2	4	2	1
3	4	2	1
4	3	2	1
5	3	1	1
6	3	1	1
7	3	1	1
8	3	2	1
9	4	2	1
10	3	1	1
11	4	2	1
12	4	2	1
13	1	1	1
14	3	2	1
15	4	2	1
16	3	1	1
17	4	1	1
18	3	1	2
19	4	1	1
20	4	1	1
21	3	2	2
22	1	2	2
23	2	2	1
24	3	2	1
25	3	2	2
26	3	2	1
27	3	2	1
28	4	2	2
29	4	2	1
30	4	2	1

**Keterangan :**

Usia :

1 = 14 tahun

2 = 15 tahun

3 = 16 tahun

4 = 17 tahun

Jenis Kelamin :

1 = Laki-laki

2 = Perempuan

Jenis Vaksin :

1 = Coronavac

2 = Pfizer



**Lampiran 5 : MASTER TABEL**

No.	UMUR	JENIS KELAMIN	JENIS VAKSIN
1.	17	1	1
2.	17	2	1
3.	16	1	1
4.	15	2	1
5.	16	2	1
6.	15	2	1
7.	17	2	1
8.	17	1	1
9.	17	2	1
10.	16	2	1
11.	16	2	1
12.	16	2	1
13.	15	1	1
14.	17	2	1
15.	17	1	1
16.	17	2	1
17.	16	1	1
18.	16	2	1
19.	17	2	1
20.	17	2	1
21.	16	2	1
22.	17	2	1
23.	17	2	1
24.	17	2	1
25.	17	2	1
26.	17	1	1
27.	16	2	1
28.	17	1	1
29.	17	2	1
30.	17	1	1
31.	17	2	1
32.	16	1	1
33.	17	2	1
34.	16	2	1
35.	17	2	1
36.	17	1	1
37.	17	1	1
38.	17	1	1
39.	16	2	1
40.	16	1	1
41.	17	1	1
42.	17	1	1
43.	16	1	1
44.	17	1	1
45.	17	1	1

46.	17	2	1
47.	17	2	1
48.	16	2	1
49.	17	2	1
50.	17	2	1
51.	17	2	1
52.	17	2	1
53.	17	1	1
54.	17	2	1
55.	16	1	1
56.	17	1	1
57.	17	1	1
58.	17	1	1
59.	17	1	1
60.	17	1	2
61.	17	1	1
62.	17	2	1
63.	17	2	1
64.	17	2	1
65.	16	2	1
66.	17	2	1
67.	17	2	1
68.	17	2	1
69.	17	2	1
70.	16	2	1
71.	17	2	1
72.	16	2	1
73.	16	2	1
74.	17	2	1
75.	17	1	1
76.	16	1	1
77.	17	1	1
78.	17	2	1
79.	17	2	1
80.	16	2	1
81.	17	1	1
82.	17	2	1
83.	17	1	1
84.	17	1	1
85.	17	2	1
86.	17	1	2
87.	17	2	1
88.	17	1	1
89.	17	2	1
90.	17	2	1
91.	15	1	1
92.	16	1	1
93.	16	2	1

94.	17	2	1
95.	17	1	1
96.	17	1	1
97.	16	2	1
98.	16	2	1
99.	17	2	1
100.	17	2	1
101.	16	2	1
102.	16	2	1
103.	17	1	1
104.	16	1	1
105.	16	2	1
106.	16	2	1
107.	17	1	1
108.	16	1	1
109.	16	2	1
110.	16	2	1
111.	16	2	1
112.	16	2	1
113.	17	1	1
114.	15	1	1
115.	16	1	1
116.	15	1	1
117.	16	2	1
118.	16	2	1
119.	16	2	2
120.	16	2	1
121.	16	2	1
122.	16	2	1
123.	15	2	1
124.	16	2	1
125.	16	2	1
126.	16	2	1
127.	17	2	1
128.	17	1	1
129.	17	2	1
130.	17	2	1
131.	17	2	1
132.	17	2	1
133.	16	2	1
134.	17	2	1
135.	17	2	1
136.	16	1	1
137.	17	2	1
138.	17	2	1
139.	17	2	1
140.	16	2	1
141.	17	2	1

142.	17	2	1
143.	16	2	1
144.	17	1	1
145.	17	1	1
146.	17	1	1
147.	17	2	1
148.	15	2	1
149.	16	2	1
150.	17	2	1
151.	17	2	1
152.	17	2	1
153.	17	2	1
154.	17	1	1
155.	16	2	1
156.	17	2	1
157.	17	2	1
158.	17	2	1
159.	17	1	1
160.	16	1	1
161.	16	2	1
162.	15	2	1
163.	16	2	1
164.	16	2	1
165.	15	1	1
166.	16	2	1
167.	16	1	1
168.	15	1	1
169.	16	1	1
170.	15	2	1
171.	16	2	1
172.	16	2	1
173.	16	1	1
174.	15	2	1
175.	16	2	1
176.	15	1	1
177.	16	1	1
178.	16	1	1
179.	15	1	1
180.	16	1	1
181.	17	1	1
182.	16	1	1
183.	16	1	1
184.	15	2	1

185.	15	2	1
186.	16	2	1
187.	16	1	1
188.	16	1	1
189.	16	1	1
190.	16	2	1
191.	15	1	1
192.	16	2	1
193.	16	1	1
194.	15	1	1
195.	16	1	1
196.	15	1	1
197.	16	2	1
198.	15	2	1
199.	15	2	1
200.	16	1	1
201.	16	1	1
202.	15	1	1
203.	15	1	1
204.	15	1	1
205.	15	2	1
206.	16	1	1
207.	16	2	1
208.	16	1	1
209.	15	2	1
210.	16	1	1
211.	15	1	1
212.	16	1	1
213.	16	1	1
214.	17	1	1
215.	16	1	1
216.	15	2	1
217.	16	2	1
218.	16	2	1
219.	16	2	1
220.	16	2	1
221.	16	2	1
222.	15	2	1
223.	15	2	1

224.	16	2	1
225.	16	1	1
226.	15	1	1
227.	16	2	1
228.	16	2	1
229.	16	2	1
230.	16	2	1
231.	16	2	1
232.	16	2	1
233.	16	2	1
234.	15	2	1
235.	17	1	1
236.	16	2	1
237.	16	2	1
238.	16	2	1
239.	17	2	1
240.	17	2	1
241.	17	2	1
242.	17	2	1
243.	17	2	1
244.	17	2	1
245.	17	2	1
246.	17	2	1
247.	17	2	1
248.	16	2	1
249.	17	2	1
250.	16	2	1
251.	16	2	1
252.	17	1	1
253.	17	1	1
254.	17	2	1
255.	17	2	1
256.	17	2	1
257.	17	2	1
258.	17	1	1
259.	17	1	1
260.	16	1	1
261.	17	2	1
262.	17	2	1

263.	17	2	1
264.	16	2	1
265.	17	1	1
266.	17	1	1
267.	17	1	1
268.	17	1	1
269.	17	1	1
270.	16	1	1
271.	17	1	1
272.	17	1	1
273.	16	2	1
274.	17	2	1
275.	17	2	1
276.	17	2	1
277.	17	2	1
278.	17	2	1
279.	16	1	1
280.	17	1	1
281.	16	1	1
282.	17	1	1
283.	17	2	1
284.	16	1	1
285.	17	1	1
286.	17	2	1
287.	16	2	1
288.	16	2	1
289.	17	2	1
290.	17	2	1
291.	17	1	1
292.	17	1	1
293.	17	2	1
294.	17	2	1
295.	17	1	1
296.	17	1	1
297.	17	1	1
298.	16	2	1
299.	17	2	1
300.	17	2	1
301.	17	2	1

302.	17	2	1
303.	16	2	1
304.	16	2	1
305.	17	2	1
306.	17	1	1
307.	17	2	1
308.	15	2	1
309.	17	1	1
310.	15	2	1
311.	15	2	1
312.	15	2	1
313.	16	2	1
314.	16	2	1
315.	16	2	1
316.	16	1	1
317.	16	2	1
318.	16	2	1
319.	15	2	1
320.	16	2	1
321.	15	2	1
322.	16	2	1
323.	16	1	1
324.	15	1	1
325.	16	1	1
326.	16	1	1
327.	15	1	1
328.	16	1	2
329.	15	2	1
330.	15	2	1
331.	15	1	1
332.	15	2	1
333.	15	2	1
334.	16	2	2
335.	15	2	1
336.	17	1	1
337.	16	1	1
338.	16	1	1
339.	16	1	1
340.	15	1	1



341.	15	2	1
342.	16	2	1
343.	16	2	1
344.	16	2	1
345.	15	2	1
346.	15	1	1
347.	16	2	1
348.	16	2	1
349.	16	2	1
350.	16	2	1
351.	15	2	1
352.	17	1	2
353.	15	1	1
354.	15	2	1

Karakteristik Responden :

Keterangan :

- Jenis Kelamin :
  - 1 = Laki-laki
  - 2 = Perempuan
- Jenis vaksin yang diterima :
  - 1 = Coronavac (Sinovac)
  - 2 = Pfizer-BionTech

### Reaksi KIPI Dosis I

KIPI 1	KIPI 2	KIPI 3	KIPI 4	KIPI 5	KIPI 6	KIPI 7	KIPI 8	KIPI 9	KIPI 10	KIPI 11	KIPI 12	KIPI 13	KIPI 14	KIPI 15
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	1	1	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	1	1	0	0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	1	1	1	1	0	1	1	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	1	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	1	0	1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	1	0	0	1	0	0	0
0	0	0	1	0	0	0	1	1	1	0	0	0	0	0
0	0	0	1	1	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	1	1	0	0	1	0	0	0	0	0	0

1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	1	0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	0	0	1	0	0	0	0
0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	1	0	1	0	1	1	0	0	0	0	0	0
1	0	0	0	1	1	0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	1	1	1	0	0	1	1	0	0	0	0	0	0
1	0	1	1	1	1	1	1	1	1	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	1	1	0	0	1	0	0	0
1	0	1	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	1	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0

1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	1	0	1	1	1	0	0	1	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	1	1	1	1	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	1	0	0	0	1	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	1	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	1	0	0	0	0	0	0	0	0	1	0	0	0
1	1	1	1	0	1	0	1	0	0	0	0	0	0	0
0	0	0	0	1	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	1	1	1	0	0	0	0	0	1	0	0	0
1	1	0	0	1	1	0	0	1	0	0	1	0	0	0
0	1	0	1	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	1	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	1	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	1	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	1	0	0	0	0	0	1	0	0	0	0	0

0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	1	0	1	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	1	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	1	0	1	1	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	1	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	1	1	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
0	1	0	1	0	0	0	0	0	1	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	1	0	0	1	0	0	0	0
0	0	0	0	0	0	1	0	0	1	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	1	0	0	0
1	0	1	1	0	0	0	0	1	1	0	0	0	0	0
1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
1	0	0	1	1	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	1	0	1	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	1	1	0	0	0	0	1	1	0	0	0	0	0	0

1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	1	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
1	0	0	1	1	1	1	0	1	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	1	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	1	1	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	1	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	1	1	0	0	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	1	0	0	0	0	0	0	1	0	0	0
0	0	0	1	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	1	0	0	0	0	0	0

1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	1	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	1	0	1	0	0	0	0
1	0	1	1	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	1	0	1	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1	1	0	1	0	1	0	1	1	0	0	0	0	0	0
1	0	0	0	1	1	0	0	0	0	0	0	0	0	0
1	0	0	0	1	1	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	1	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	1	1	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
1	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	1	1	1	1	0	1	1	0	0	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
1	0	0	0	0	0	0	1	1	0	0	1	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	1	0	0	0	1	0	0	0	0	0	0

0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	1	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
1	0	0	1	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	1	0	0	1	0	0	0	0
1	0	1	0	1	0	0	0	0	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	1	0	0	0	0	1	0	0	0	0
0	0	0	0	1	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	1	0	0	1	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1	0	0	0	0	1	0	1	1	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
1	0	0	1	1	0	0	0	1	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1



1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	1	0	0	0	0	1	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	1	0	1	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	1	0	0	0	1	1	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	1	0	0	0	0
1	0	0	0	1	0	0	1	1	0	1	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	1	0	0	1	0	0	0	0	0	0
1	0	0	0	0	1	0	0	0	0	0	0	1	1	0
1	1	1	0	0	1	0	1	1	0	1	1	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	1	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	1	0	0	0	1	0	1	0	0	0	0
1	0	0	0	0	0	0	0	1	0	1	1	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	1	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1	0	0	1	1	0	0	0	1	0	0	1	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
1	0	0	0	0	1	0	0	0	0	0	0	0	0	0
0	0	0	0	1	1	1	0	1	0	1	1	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0

0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
0	0	0	1	0	0	0	1	1	0	0	1	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	1	1	0	0	1	0	0	0
1	0	0	0	1	1	0	1	1	0	1	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	1	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	1	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1

**Keterangan :**

KIPI 1 (Nyeri pada lokasi suntikan)

KIPI 2 (Kemerahan di lokasi suntikan)

KIPI 3 (Bengkak di lokasi suntikan)

KIPI 4 (Demam)

KIPI 5 (Sakit Kepala)

KIPI 6 (Pusing)

KIPI 7 (Mual/Muntah)

KIPI 8 (Nyeri otot)

KIPI 9 (Kelelahan)

KIPI 10 (Menggigil)

KIPI 11 (Mengantuk)

KIPI 12 (Perubahan nafsu makan)

KIPI 13 (Kesulitan Bernafas)

KIPI 14 (Nyeri dada)

KIPI 15 (Tidak ada)

**Keterangan Koding :**

0 = Tidak

1 = Ya

### Reaksi KIPI dosis 2

KIPI 1	KIPI 2	KIPI 3	KIPI 4	KIPI 5	KIPI 6	KIPI 7	KIPI 8	KIPI 9	KIPI 10	KIPI 11	KIPI 12	KIPI 13	KIPI 14	KIPI 15
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	1	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	1	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	1	1	1	0	1	1	1	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	1	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	1	1	0	0	1	0	0	0
0	0	0	1	0	1	0	1	0	0	0	0	0	0	0
0	0	0	1	1	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	1	1	1	1	0	0	1	0	0	0	0	0

1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	1	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1	0	0	0	1	0	0	0	1	0	0	1	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	1	1	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	1	0	0	1	0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	1	1	0	0	1	0	0	1	0	0	0
1	0	1	1	1	1	1	1	1	1	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
1	0	1	0	0	0	0	1	0	1	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	1	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
0	0	1	0	0	0	0	0	0	0	1	0	0	0	0
1	0	1	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0

0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
0	0	1	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	1	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	1	1	0	0	1	0	0	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	1	0	0	0	0	0	0	0	0	0	1	0	0	0
1	0	1	1	1	1	0	1	1	0	0	0	0	0	0
1	0	0	1	1	0	0	0	0	0	0	0	0	0	0
1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
1	1	0	0	0	0	0	0	1	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	1	1	0	0	0	0	0	0	0	0	0
1	1	1	1	1	1	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	1	1	0	0	0	0	0	1	0	0	0
1	1	0	0	1	1	0	0	1	0	0	1	0	0	0
0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	1	1	0	1	1	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	1	0	0	0
1	0	0	1	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	1	1	0	1	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	1	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	1	1	1	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	1	0	0	0	1	1	1	0	1	1	0	0

0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	1	1	1	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	1	0	0	1	1	0	0	0
1	0	0	0	0	0	0	1	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	1	0	1	1	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	1	0	0	0	0	0	1	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	1	1	0	0	0	0	0	0	0	0	0	0	0
0	0	1	0	0	0	1	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	1	0	1	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	1	1	0	0	0	0	1	0	0	0	0	0	0
1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	1	0	0	1	0	0	0	0
0	0	0	0	0	1	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1

1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	1	0	0	0	0	0	0	1	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	1	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	1	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	1	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	1	1	0	0	1	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	1	0	1	0	0	0	1	0	0	0	0	0	0	0

1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	1	1	1	0	0	1	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	1	0	1	1	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	1	1	0	1	1	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	1	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	1	0	0	0
0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	1	1	0	1	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	1	0	0	1	0	0	0
0	0	0	1	1	1	0	1	1	0	0	0	1	1	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	1	1	0	0	1	0	0	0
0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0



0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	1	1	0	1	0	0	0	0	0	0	0
0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	1	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	1	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	1	0	0	1	0	0	0	0
1	1	1	0	0	0	0	1	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
1	0	1	0	0	0	0	0	0	0	0	1	0	0	0
0	0	0	0	1	1	0	1	1	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	1	1	0	0	1	1	0	1	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	1	0	0	1	0	0	0	0
0	0	0	0	0	0	0	1	1	0	1	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
1	0	0	1	1	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1

0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	1	1	0	0	0
0	0	0	0	0	0	0	0	1	0	1	1	0	0	0
1	0	0	0	0	0	0	0	1	0	0	1	0	0	0
0	0	0	0	0	0	0	1	0	0	1	0	0	0	0
1	0	0	0	0	1	0	0	0	0	1	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	1	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	1	0	0	0	0
1	1	0	0	0	0	0	1	0	0	1	1	0	0	0
1	0	0	0	0	1	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	1	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	1	1	1	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	1	1	0	0	0	0	0	0
0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
0	0	0	0	1	1	0	0	1	0	1	1	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0

0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
1	0	0	1	0	0	0	1	1	0	1	1	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	1	0	1	1	0	0	0
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	1	0	1	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
0	0	0	0	0	0	0	0	0	0	0	0	0	0	1

**Keterangan :**

KIPI 1 (Nyeri pada lokasi suntikan)

KIPI 2 (Kemerahan di lokasi suntikan)

KIPI 3 (Bengkak di lokasi suntikan)

KIPI 4 (Demam)

KIPI 5 (Sakit Kepala)

KIPI 6 (Pusing)

KIPI 7 (Mual/Muntah)

KIPI 8 (Nyeri otot)

KIPI 9 (Kelelahan)

KIPI 10 (Menggigil)

KIPI 11 (Mengantuk)

KIPI 12 (Perubahan nafsu makan)

KIPI 13 (Kesulitan Bernafas)

KIPI 14 (Nyeri dada)

KIPI 15 (Tidak ada)

**Keterangan Koding :**

0 = Tidak

1 = Ya

**Lama Gejala atau Jangka Waktu Reaksi KIPI dan Kemampuan Beraktifitas sehari-hari saat Mengalami KIPI**

Jangka Waktu KIPI 1	Jangka Waktu KIPI 2	Kemampuan Beraktifitas (KIPI dosis 1)	Kemampuan Beraktifitas (KIPI dosis 2)
1	1	1	1
2	2	2	2
2	2	2	2
1	1	1	1
1	1	1	1
2	3	2	2
2	2	2	2
2	1	2	1
2	2	2	2
2	2	2	2
2	2	2	2
2	2	2	2
1	1	1	1
1	2	1	2
1	1	1	1
3	2	2	2
1	1	1	1
3	3	3	2
3	1	2	1
1	1	1	1
3	2	3	2
2	1	2	1
1	2	1	2
2	2	2	2
3	3	2	2
1	2	1	2
3	2	3	2
1	1	1	1
1	1	1	1
2	1	2	1
2	2	2	2
2	2	2	2
2	3	2	2
1	1	1	1
2	2	2	2

2	1	2	1
1	1	1	1
2	2	2	2
2	2	3	2
2	2	3	3
2	2	2	2
2	1	2	1
3	3	3	3
1	2	1	2
3	3	3	2
2	2	2	2
2	2	2	2
1	3	1	2
2	3	2	2
2	3	2	2
1	2	1	2
2	3	2	3
1	1	1	1
3	1	2	1
2	2	2	2
2	2	2	2
2	1	2	1
2	2	2	2
2	1	3	1
2	2	2	2
3	2	2	2
3	2	2	2
2	2	2	2
2	3	2	2
3	2	2	2
3	1	2	1
2	2	2	2
2	2	2	2
2	1	2	1
2	2	2	2
3	2	3	3
1	1	1	1
4	3	2	2
3	2	2	2
3	1	2	1
1	2	1	2

2	2	2	2
3	1	2	1
2	1	2	1
2	3	2	2
1	2	1	2
2	2	2	2
2	3	2	2
1	2	1	2
2	2	2	2
3	2	2	2
1	1	1	1
1	1	1	1
2	2	2	2
2	1	2	1
1	1	1	1
1	2	1	2
2	2	2	2
3	3	2	2
2	2	2	2
2	2	2	2
3	2	2	2
1	3	1	2
3	3	3	3
2	2	3	3
2	2	3	3
2	2	2	2
2	2	2	2
3	1	2	1
1	2	1	2
1	2	1	2
2	2	3	3
2	2	3	3
2	2	2	2
3	3	2	2
2	2	2	2
2	2	2	2
3	3	2	2
1	1	1	1
2	1	2	1
1	1	1	1
2	2	2	2

3	3	2	2
2	2	2	2
3	3	2	2
3	3	3	2
2	2	2	2
2	3	2	2
2	1	2	1
1	1	1	1
2	2	2	2
1	3	1	2
2	1	2	1
2	2	3	3
2	2	3	2
1	2	1	2
2	1	2	1
2	1	2	1
2	3	2	3
2	2	2	2
1	1	1	1
2	2	2	2
3	3	3	3
1	1	1	1
3	3	2	2
3	4	2	2
3	1	2	1
2	2	2	2
1	2	1	2
1	1	1	1
2	2	2	2
1	1	1	1
2	2	2	2
2	2	3	3
1	1	1	1
1	2	1	2
2	3	2	2
2	1	2	1
1	1	1	1
3	3	2	2
1	1	1	1
3	3	2	2
1	2	1	2

2	1	2	1
2	1	2	1
2	3	2	2
2	2	3	2
1	1	1	1
2	2	2	2
2	2	2	2
2	2	2	2
3	2	2	2
2	1	2	1
2	2	2	2
3	3	2	2
2	3	2	2
2	2	2	2
2	2	2	2
2	1	2	1
1	1	1	1
3	2	2	2
3	2	2	2
2	2	2	2
2	2	2	2
2	1	2	1
2	2	2	2
2	2	3	2
2	1	2	1
2	1	2	1
2	2	2	2
2	2	2	2
2	2	2	2
2	3	2	2
2	2	2	2
2	3	2	2
3	2	2	2
1	1	1	1
2	1	2	1
3	2	3	2
2	2	2	2
1	1	1	1
2	2	2	2
2	2	2	2
2	2	3	2



2	2	2	2
1	1	1	1
2	1	2	1
2	2	2	2
3	1	3	1
2	2	2	2
3	3	2	2
2	1	2	1
2	2	2	2
3	2	2	2
2	2	2	2
2	2	2	2
2	1	2	1
2	2	2	2
3	2	3	2
2	1	2	1
1	1	1	1
1	1	1	1
2	2	2	2
3	1	3	1
3	3	2	2
2	2	2	2
2	2	2	2
3	2	2	2
3	2	2	2
1	1	1	1
2	2	2	2
3	3	2	2
3	2	2	2
3	1	2	1
2	2	2	2
3	1	2	1
2	2	2	2
4	2	2	2
1	1	1	1
2	2	2	2
2	3	2	3
3	3	2	2
4	3	2	2
2	2	2	2

2	2	3	3
2	2	3	2
2	2	3	2
2	2	2	2
1	2	1	2
3	3	3	3
2	2	2	2
3	3	2	2
1	2	1	2
2	2	2	2
2	2	2	3
2	1	2	1
2	1	2	1
3	3	2	2
3	3	2	2
4	4	2	2
3	3	3	3
3	1	2	1
2	2	2	2
2	2	3	3
2	1	2	1
3	3	2	2
1	1	1	1
1	1	1	1
3	2	2	2
2	2	2	2
3	1	2	1
2	2	2	2
2	2	2	2
2	2	2	2
2	2	2	2
2	2	2	2
2	2	2	2
2	2	2	2
2	2	2	2
2	2	2	2
1	2	1	2
3	2	2	2
3	2	2	2
3	2	2	2
2	2	3	2
2	2	2	2

2	2	2	2
2	2	2	2
2	1	2	1
3	4	2	2
2	3	2	2
2	1	2	1
2	1	2	1
2	2	3	3
2	2	2	2
2	1	2	1
3	1	2	1
2	1	2	1
3	2	2	2
2	2	2	2
2	2	2	2
2	2	2	2
2	2	3	2
2	2	2	2
3	2	2	3
1	1	1	1
3	2	2	2
2	2	2	2
2	1	2	1
2	2	3	2
1	2	1	2
2	2	2	2
2	2	2	2
2	2	2	2
2	2	2	2
2	1	2	1
2	2	2	2
3	1	2	1
3	3	3	2
2	2	2	2
2	2	2	2
3	1	2	1
3	1	2	1
2	1	2	1
2	2	2	2
2	2	2	2
2	1	3	1

2	1	2	1
2	2	2	2
3	2	2	2
2	2	2	2
3	2	2	2
3	2	2	2
2	2	2	2
2	1	2	1
2	2	2	2
2	2	3	2
2	2	2	2
2	2	2	2
4	3	2	2
2	2	2	2
2	2	2	2
1	1	1	1
1	1	1	1
2	2	2	2
2	2	2	3
2	2	2	2
3	2	2	2
2	1	2	1
2	2	2	2
1	2	1	2
2	2	2	2
2	2	2	2
2	3	2	2
2	2	2	2
3	1	2	1
2	2	3	2
1	1	1	1
1	1	1	1

Keterangan Jangka Waktu Reaksi KIPI:

1 = Tidak mengalami KIPI

2 = <24 jam

3 = 24-72 jam

4 = >72 jam

Keterangan Kemampuan Beraktifitas sehari-hari saat mengalami KIPI :

1 = Tidak

2 = Ya

### Tindakan yang dilakukan Saat Mengalami Reaksi KIPI

Tindakan yang dilakukan saat KIPI dosis 1	Tindakan yang dilakukan saat KIPI dosis 2	KIPI lainnya
1	6	1
2	2	1
2	1	1
1	1	1
1	1	1
2	2	1
3	2	1
6	1	1
4	2	1
1	1	1
1	2	1
1	2	1
1	1	1
1	1	1
1	1	1
2	2	1
1	1	1
2	2	1
2	1	1
1	1	1
2	2	1
1	1	1
1	2	1
2	2	1
1	1	1
1	1	1
2	2	1
1	1	1
2	2	1
2	1	1
2	2	1
2	2	1
2	2	1
1	1	1
2	2	1
2	1	1
1	1	1

1	3	1
2	2	1
2	2	1
1	1	1
1	1	1
2	1	1
1	1	1
1	1	1
1	1	1
2	2	1
1	2	1
3	3	1
1	1	1
3	2	1
2	2	1
1	1	1
2	1	1
3	1	1
1	1	1
3	1	1
2	2	1
3	3	1
1	1	1
3	1	1
2	2	1
2	2	1
3	2	1
2	2	1
3	1	2
2	2	1
2	2	1
2	1	1
3	2	1
3	2	1
1	1	1
2	2	1
2	2	1
1	1	1
1	2	1
1	1	1
2	1	1

3	3	1
2	2	1
1	1	1
2	2	1
2	2	1
1	1	1
3	3	1
1	2	1
1	1	1
1	1	1
1	1	1
3	1	1
1	1	1
1	2	1
2	2	1
1	1	1
2	2	1
1	1	1
1	1	1
1	2	1
2	2	1
2	2	1
2	2	1
2	2	1
1	1	1
2	3	1
1	2	1
1	3	3
2	2	1
3	3	4
2	2	1
1	1	1
2	2	1
1	1	1
1	1	1
1	1	1
1	1	1
1	1	1
2	2	1
1	1	1
2	2	1

1	1	1
2	3	1
1	1	1
3	1	1
1	1	1
2	2	1
2	2	1
1	1	1
1	1	1
2	2	1
1	2	1
1	2	1
3	1	1
1	1	5
2	2	1
2	2	1
1	1	1
2	2	1
2	2	1
1	1	1
2	2	2
3	5	1
1	1	1
2	2	1
1	2	1
1	1	1
2	2	1
1	1	1
1	1	1
2	2	1
1	1	1
1	2	1
2	2	1
2	1	1
1	1	1
2	2	1
1	1	1
2	2	1
1	2	1
2	1	1
2	1	1



2	3	1
3	3	1
1	1	1
2	2	1
1	2	1
2	2	1
1	2	1
3	1	1
2	2	1
2	2	1
2	2	1
2	2	1
2	2	1
1	1	1
1	1	1
2	2	1
1	2	1
2	2	1
3	1	1
2	1	1
3	2	1
2	2	1
2	1	1
5	1	1
3	3	1
2	2	1
2	1	1
2	2	1
3	3	1
2	2	1
1	2	1
1	1	1
1	1	1
3	2	1
3	3	1
1	1	1
2	2	1
3	2	1
1	1	1
1	2	1
1	1	1

2	1	1
2	2	1
2	1	1
2	1	1
2	1	1
2	1	1
2	2	1
1	1	1
2	2	1
2	2	1
2	2	1
3	1	1
2	2	1
2	3	1
2	1	1
1	1	1
1	1	1
3	1	1
1	1	1
2	2	1
1	1	1
2	3	1
2	2	1
1	2	1
1	1	1
2	2	1
2	2	1
2	2	1
4	1	1
1	2	1
2	1	1
2	2	1
2	1	1
1	1	1
2	1	1
3	3	1
1	1	1
2	2	1
3	2	1
3	2	1
2	2	1

2	2	1
2	2	1
1	2	1
2	2	1
2	2	1
2	2	1
1	3	1
2	2	1
2	2	1
2	1	1
1	1	1
2	2	1
2	2	1
2	2	1
2	2	1
1	1	1
2	2	1
2	2	1
2	1	1
2	2	1
1	1	1
1	1	1
1	1	1
2	1	1
2	1	1
3	3	1
2	1	1
2	2	1
2	2	1
2	2	1
2	2	1
1	3	1
2	2	1
1	2	1
3	3	1
2	2	1
1	2	1
2	2	1
2	2	1
2	2	1
2	2	1

2	1	6
2	2	1
3	2	1
2	1	1
2	1	1
2	2	1
2	2	1
1	1	1
2	1	1
3	1	1
2	1	1
2	2	1
2	2	1
2	2	1
2	2	1
2	2	1
2	3	1
3	2	1
1	1	1
1	2	1
2	2	1
2	1	1
2	2	1
1	2	1
1	2	1
2	2	1
2	2	1
2	2	1
1	1	1
2	2	1
2	1	2
3	2	1
3	3	1
2	2	1
2	1	1
1	1	1
3	1	1
1	2	1
2	2	1
3	1	1
2	1	1
1	1	1

2	2	1
2	2	1
1	1	1
1	1	1
2	2	1
1	1	1
1	1	1
3	3	1
2	2	1
2	2	1
2	2	1
2	2	1
2	2	1
1	1	1
1	1	1
2	2	1
2	2	1
2	2	1
1	2	1
2	1	1
2	3	1
1	2	1
3	1	1
3	1	1
2	2	1
2	3	1
3	1	1
2	3	1
1	1	1
1	1	1

**Keterangan Tindakan yang dilakukan saat mengalami Reaksi KIPI :**

- 1 = Tidak mengalami KIPI
- 2 = Istirahat, tidur dan mengurangi aktifitas
- 3 = Mengonsumsi obat atau minuman lain untuk mengurangi gejala
- 4 = Mengompres area suntikan
- 5 = Ke Pelayanan Kesehatan
- 6 = Mandi setelah vaksin

**Keterangan Reaksi KIPI lainnya :**

- 1 = Tidak ada
- 2 = Pingsan
- 3 = Tangan terasa lemah
- 4 = Perut terasa panas
- 5 = Tangan kram
- 6 = Linglung

## Lampiran 9 (Gambaran Reaksi KIPI)

Reaksi KIPI lokal dosis 1 (n = 201)

Reaksi KIPI Lokal	n	%	<i>Percent of cases (%)</i>
Nyeri Pada Lokasi Suntikan	197	82,1	98,0
Kemerahan di lokasi suntikan	17	7,1	8,5
Bengkak di lokasi suntikan	26	10,8	12,9
Total	240	100,0	119,4

Reaksi KIPI lokal dosis 2 (n = 170)

Reaksi KIPI Lokal	n	%	<i>Percent of cases (%)</i>
Nyeri Pada Lokasi Suntikan	162	77,9	95,3
Kemerahan di lokasi suntikan	17	8,2	10,0
Bengkak di lokasi suntikan	29	13,9	17,1
Total	208	100,0	122,4

Reaksi KIPI lokal di kedua dosis/tidak :

Reaksi KIPI Lokal	Pada Kedua Dosis	Tidak pada Kedua Dosis
Nyeri Pada Lokasi Suntikan	128 (36,2%)	226 (63,8%)
Kemerahan di lokasi suntikan	7 (2%)	347 (98,0%)
Bengkak di lokasi suntikan	10 (2,8%)	344 (97,2%)

Reaksi KIPI Sistemik dosis 1 (n = 231)

Reaksi KIPI Lokal	n	%	<i>Percent of cases (%)</i>
Demam	37	8,6	16,0
Sakit Kepala	43	10,0	18,6
Pusing	41	9,5	17,7
Mual/Muntah	4	0,9	1,7
Nyeri Otot	75	17,4	32,5
Kelelahan	115	26,6	49,8
Menggigil	6	1,4	2,6
Mengantuk	59	13,7	25,5
Perubahan Nafsu Makan	52	12,0	22,5

Reaksi KIPI Sistemik dosis 2 (n = 183)

Reaksi KIPI Lokal	n	%	<i>Percent of cases (%)</i>
Demam	26	7,2	14,2
Sakit Kepala	33	9,2	18,0
Pusing	40	11,1	21,9
Mual/Muntah	5	1,4	2,7
Nyeri Otot	55	15,3	23,4
Kelelahan	84	23,4	45,9
Menggigil	6	1,7	3,3
Mengantuk	69	19,2	37,7
Perubahan Nafsu Makan	41	11,4	22,4

Reaksi Sistemik di kedua dosis/tidak : (N = 354)

Reaksi KIPI Lokal	Pada Kedua Dosis	Tidak pada Kedua Dosis
Demam	17 (4,8%)	337 (95,2%)
Sakit Kepala	19 (5,4%)	335 (94,6%)
Pusing	21 (5,9%)	333 (94,1%)
Mual/Muntah	2 (0,6%)	352 (99,4%)
Nyeri otot	38 (10,7%)	316 (89,3%)
Kelelahan	57 (16,1%)	297 (83,9%)
Menggigil	1 (0,3%)	353 (99,7)
Mengantuk	23 (6,5%)	331 (93,5%)
Perubahan nafsu makan	23 (6,5%)	331 (93,5%)



## Lampiran 10 : Hasil Analisa Kuantitatif

### A. Frekuensi Karakteristik Responden

#### Frequencies

		Statistics		
		Usia	JenisKelamin	JenisVaksin
N	Valid	354	354	354
	Missing	0	0	0

#### Frequency Table

		Usia			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	15 Tahun	54	15.3	15.3	15.3
	16 Tahun	141	39.8	39.8	55.1
	17 Tahun	159	44.9	44.9	100.0
	Total	354	100.0	100.0	

		JenisKelamin			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	134	37.9	37.9	37.9
	Perempuan	220	62.1	62.1	100.0
	Total	354	100.0	100.0	

		JenisVaksin			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Coronavac	348	98.3	98.3	98.3
	Pfizer	6	1.7	1.7	100.0
	Total	354	100.0	100.0	

#### KIPI1atauTidak

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak Mengalami KIPI	65	18.4	18.4	18.4
	KIPI	289	81.6	81.6	100.0
	Total	354	100.0	100.0	

#### KIPI2atauTidak

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak Mengalami KIPI	103	29.1	29.1	29.1
	KIPI	251	70.9	70.9	100.0
	Total	354	100.0	100.0	

### Distribusi Reaksi KIPI

#### JENISKIPI1

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Reaksi Gabungan	145	50.2	50.2	50.2
	Reaksi Lokal	56	19.4	19.4	69.6
	Reaksi Sistemik	88	30.4	30.4	100.0
	Total	289	100.0	100.0	

#### JENISKIPI2

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Reaksi Gabungan	103	41.0	41.0	41.0
	Reaksi Lokal	68	27.1	27.1	68.1
	Reaksi Sistemik	80	31.9	31.9	100.0
	Total	251	100.0	100.0	

### USIA \* JENISKIPI1 Crosstabulation

Count

		JENISKIPI1			Total
		Reaksi Gabungan	Reaksi Lokal	Reaksi Sistemik	
USIA	15 TAHUN	25	10	9	44
	16 TAHUN	60	20	40	120
	17 TAHUN	60	26	39	125
Total		145	56	88	289

### USIA \* JENISKIPI2 Crosstabulation

Count

		JENISKIPI2			Total
		Reaksi Gabungan	Reaksi Lokal	Reaksi Sistemik	
USIA	15 TAHUN	13	12	10	35
	16 TAHUN	40	26	37	103
	17 TAHUN	50	30	33	113
Total		103	68	80	251

### JENISKELAMIN \* JENISKIPI1 Crosstabulation

Count

		JENISKIPI1			Total
		Reaksi Gabungan	Reaksi Lokal	Reaksi Sistemik	
JENISKELAMIN	LAKI-LAKI	52	23	31	106
	PEREMPUAN	93	33	57	183
Total		145	56	88	289

### JENISKELAMIN \* JENISKIPI2 Crosstabulation

Count

		JENISKIPI2			Total
		Reaksi Gabungan	Reaksi Lokal	Reaksi Sistemik	
JENISKELAMIN	LAKI-LAKI	26	33	29	88
	PEREMPUAN	77	35	51	163
Total		103	68	80	251

### JENISVAKSIN \* JENISKIPI1 Crosstabulation

Count

		JENISKIPI1			Total
		Reaksi Gabungan	Reaksi Lokal	Reaksi Sistemik	
JENISVAKSIN	Coronavac	143	54	86	283
	Pfizer	2	2	2	6
Total		145	56	88	289

### JENISVAKSIN \* JENISKIPI2 Crosstabulation

Count

		JENISKIPI2			Total
		Reaksi Gabungan	Reaksi Lokal	Reaksi Sistemik	
JENISVAKSIN	Coronavac	102	67	76	245
	Pfizer	1	1	4	6
Total		103	68	80	251

### Frekuensi Reaksi KIPI Lokal Dosis 2

#### \$Reaksi\_Lokal\_Dosis\_2 Frequencies

		Responses		
		N	Percent	Percent of Cases
\$Reaksi_Lokal_Dosis_2 <sup>a</sup>	Nyeridosi2	162	77.9%	95.3%
	Kemerahandosis2	17	8.2%	10.0%
	Bengkakdosis2	29	13.9%	17.1%
Total		208	100.0%	122.4%

### Multiple Response

#### Case Summary

	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
\$Reaksi_Sistemik_Dosis_1 <sup>a</sup>	231	100.0%	0	0.0%	231	100.0%

a. Dichotomy group tabulated at value 1.

## Frekuensi Reaksi KIPI Sistemik Dosis 1

### \$Reaksi\_Sistemik\_Dosis\_1 Frequencies

		Responses		Percent of Cases
		N	Percent	
\$Reaksi_Sistemik_Dosis_1 <sup>a</sup>	Demam	37	8.6%	16.0%
	Sakitkepala	43	10.0%	18.6%
	Pusing	41	9.5%	17.7%
	Mualmuntah	4	0.9%	1.7%
	Nyeriotot	75	17.4%	32.5%
	Kelelahan	115	26.6%	49.8%
	menggigil	6	1.4%	2.6%
	mengantuk	59	13.7%	25.5%
	Perubahannafsumakan	52	12.0%	22.5%
	Total	432	100.0%	187.0%

a. Dichotomy group tabulated at value 1.

## Multiple Response

### Case Summary

	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
\$Reaksi_Sistemik_Dosis_2 <sup>a</sup>	183	100.0%	0	0.0%	183	100.0%

a. Dichotomy group tabulated at value 1.

## Frekuensi Reaksi KIPI Sistemik Dosis 2

### \$Reaksi\_Sistemik\_Dosis\_2 Frequencies

		Responses		Percent of Cases
		N	Percent	
\$Reaksi_Sistemik_Dosis_2 <sup>a</sup>	Demam	26	7.2%	14.2%
	SakitKepala	33	9.2%	18.0%
	Pusing	40	11.1%	21.9%
	Mualmuntah	5	1.4%	2.7%
	Nyeriotot	55	15.3%	30.1%

	Kelelahan	84	23.4%	45.9%
	Mengigil	6	1.7%	3.3%
	Mengantuk	69	19.2%	37.7%
	Perubahannafsumakan	41	11.4%	22.4%
Total		359	100.0%	196.2%

a. Dichotomy group tabulated at value 1.

## Multiple Response

### Case Summary

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
\$Reaksi_Berat_Dosis_1 <sup>a</sup>	1	100.0%	0	0.0%	1	100.0%

a. Dichotomy group tabulated at value 1.

## Frekuensi Reaksi KIPI Berat Dosis 1

### \$Reaksi\_Berat\_Dosis\_1 Frequencies

		Responses		Percent of Cases
		N	Percent	
\$Reaksi_Berat_Dosis_1 <sup>a</sup>	Kesulitannafas	1	50.0%	100.0%
	Nyeridada	1	50.0%	100.0%
Total		2	100.0%	200.0%

a. Dichotomy group tabulated at value 1.

## Multiple Response

### Case Summary

	Valid		Cases Missing		Total	
	N	Percent	N	Percent	N	Percent
\$Reaksi_Berat_Dosis_2 <sup>a</sup>	2	100.0%	0	0.0%	2	100.0%

a. Dichotomy group tabulated at value 1.

## Frekuensi Reaksi KIPI Berat Dosis 2

### \$Reaksi\_Berat\_Dosis\_2 Frequencies

		Responses		Percent of Cases
		N	Percent	
\$Reaksi_Berat_Dosis_2 <sup>a</sup>	Kesulitannafas	2	66.7%	100.0%
	Nyeridada	1	33.3%	50.0%
Total		3	100.0%	150.0%

a. Dichotomy group tabulated at value 1.

## Jangka Waktu Reaksi KIPI dosis 2

### JangkaWaktuKIPI1

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak Mengalami KIPI	65	18.4	18.4	18.4
	<24 Jam	206	58.2	58.2	76.6
	24-72 jam	77	21.8	21.8	98.3
	>72 jam	6	1.7	1.7	100.0
	Total	354	100.0	100.0	

## Jangka Waktu Reaksi KIPI dosis 2

### JangkaWaktuKIPI2

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Tidak Mengalami KIPI	103	29.1	29.1	29.1
	<24 Jam	197	55.6	55.6	84.7
	24-72 jam	51	14.4	14.4	99.2
	>72 jam	3	.8	.8	100.0
	Total	354	100.0	100.0	

## Kemampuan Melakukan Aktiftas Saat KIPI Dosis 2

		AktiftasKIPI1			Cumulative
		Frequency	Percent	Valid Percent	Percent
Valid	Tidak Mengalami KIPI	65	18.4	18.4	18.4
	Ya	249	70.3	70.3	88.7
	Tidak	40	11.3	11.3	100.0
	Total	354	100.0	100.0	

## Kemampuan Melakukan Aktiftas Saat KIPI Dosis 2

		AktiftasKIPI2			Cumulative
		Frequency	Percent	Valid Percent	Percent
Valid	Tidak KIPI	103	29.1	29.1	29.1
	Ya	229	64.7	64.7	93.8
	Tidak	22	6.2	6.2	100.0
	Total	354	100.0	100.0	

## Tindakan Saat Mengalami Reaksi KIPI dosis 2

		TindakanyangdilakukanKIPI1			Cumulative
		Frequency	Percent	Valid Percent	Percent
Valid	Tidak ada	127	35.9	35.9	35.9
	Istirahat/Mengurangi Aktiftas	178	50.3	50.3	86.2
	Mengonsumsi Obat, vitamin atau minuman lain untuk mengurangi gejala KIPI	45	12.7	12.7	98.9
	Kompres area suntikan	2	.6	.6	99.4
	Ke Pelayanan Kesehatan	1	.3	.3	99.7
	Mandi setelah vaksin	1	.3	.3	100.0
	Total	354	100.0	100.0	



## Tindakan Saat Mengalami Reaksi KIPI dosis 2

		TindakanKIPI2			Cumulative
		Frequency	Percent	Valid Percent	Percent
Valid	Tidak ada	150	42.4	42.4	42.4
	Istirahat/Mengurangi Aktifitas	175	49.4	49.4	91.8
	Mengonsumsi Obat, vitamin atau minuman lain untuk mengurangi gejala KIPI	27	7.6	7.6	99.4
	Ke Pelayanan Kesehatan	1	.3	.3	99.7
	Mandi setelah Vaksin	1	.3	.3	100.0
	Total	354	100.0	100.0	

## Reaksi KIPI Lainnya

		KIPIlainnya			Cumulative
		Frequency	Percent	Valid Percent	Percent
Valid	Tidak ada	347	98.0	98.0	98.0
	Pingsan	3	.8	.8	98.9
	Tangan terasa lemah	1	.3	.3	99.2
	Perut terasa panas	1	.3	.3	99.4
	Tangan Kram	1	.3	.3	99.7
	Linglung	1	.3	.3	100.0
	Total	354	100.0	100.0	